GTHX Oct 2024 3.000 put
- GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Successful Closing of Tender Offer
- Transaction Will Maximize the Access and Uptake of COSELA® (trilaciclib), the First and Only Proactive Multilineage Myeloprotection Agent - - G1 Stockholders to Receive U.S. $7.15 Per Share in Cash - HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
- Simply Wall St.
Exploring High Growth Tech Stocks in the United States for September 2024
Over the last 7 days, the market has dropped 4.4%. As for the longer term, the market has risen by 19% in the last year. Looking forward, earnings are forecast to grow by 15% annually. In this context, identifying high growth tech stocks that can capitalize on these trends is crucial for investors seeking robust returns in a dynamic market environment.
- GlobeNewswire
Pharmacosmos Group and G1 Therapeutics Announce Expiration of Hart-Scott-Rodino Waiting Period
HOLBAEK, Denmark and RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Pharmacosmos A/S, a leader in the development of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia, and G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company focused on delivering next-generation therapies that improve the lives of those affected by cancer, today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Im
